DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel

- NxTAG® GPP is a molecular multiplex panel that detects 16 different pathogens (bacteria, viruses, parasites)
- The GPP panel is now available in countries accepting CE Mark on the non-automated MAGPIX® analysers
- This new panel allows for same-day results, leading to faster and better management of gastrointestinal infections

Saluggia, Italy, March 8, 2022 – DiaSorin (FTSE MIB: DIA) today announced that Luminex, a DiaSorin company, CE marked its xMAP® NxTAG® Gastrointestinal Pathogen Panel (GPP). This new molecular panel is a comprehensive multiplex test that detects nucleic acids from 16 of the most clinically relevant bacterial, viral, and parasitic pathogens in stool samples on the easy-to-use MAGPIX® System.

Because gastrointestinal symptoms are similar for a wide variety of infections, it can be challenging for physicians to get an accurate diagnosis and select the most appropriate treatment plan quickly enough to make a difference for patients. A study published in 2018 found that more than 192 million cases of acute gastroenteritis were reported in Europe in just one year. Rapidly identifying the causal pathogen in these situations is a pressing need, but conventional diagnostic testing can take days or longer if tests for all possible targets are run serially.

The NxTAG® GPP test provides same-day results, giving clinicians the answers they need to make timely treatment decisions, including de-escalating antibiotic use and supporting antibiotic stewardship efforts. It can run as many as 96 samples at a time, delivering higher throughput in a simplified workflow for high-volume testing laboratories. Users may also customize the targets included in the GPP test to meet the needs of their physicians.

The NxTAG GPP test covers eight types of bacteria, including *C. difficile*, *Salmonella*, and *Campylobacter*, five types of viruses, including norovirus and rotavirus; and three parasites, including *Giardia lamblia*.

“With this CE marking, clinical laboratories across Europe will be able to streamline testing for patients exhibiting gastrointestinal symptoms using the NxTAG GPP test,” said Nachum “Homi” Shamir, President of Luminex. “In particular, labs that are already using the NxTAG system for respiratory infection testing should find it easy to expand their test menus with this cost-effective NxTAG GPP test.”
For additional information, please contact:

**Riccardo Fava**
*Corporate Vice President Communication & Investor Relations*
Tel: +39.0161.487988
riccardo.fava@diasorin.it

**Emanuela Salvini**
*Investor Relator*
Tel: +39.0161.487567
emanuela.salvini@diasorin.it

---

**About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasoringroup.com](http://www.diasoringroup.com)